Locations:
SearchPhase 3 results reported in NEJM
In a phase 3 trial, inotuzumab ozogamicin demonstrated a significantly higher rate of response and minimal residual disease negativity compared to standard-of-care chemotherapy for patients with refractory or relapsed acute lymphoblastic leukemia (ALL), reports Cleveland Clinic’s Anjali S. Advani, MD, Director, Inpatient Leukemia Program.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“The prognosis for patients with ALL is poor and therapy has not changed significantly during the past decade. New therapies are needed. We hope this study will lead to FDA approval of this drug, adding a new weapon to our arsenal that improves outcomes for patients,” Dr. Advani states.
Trial results were published in the June 12 New England Journal of Medicine in an article co-authored by Dr. Advani and an international team of researchers. Also see Dr. Advani’s previous Consult QD article, Evaluating Novel Therapies in Acute Leukemia: Promising Clinical Trials Underway.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients